KLBF - PT. Kalbe Farma Tbk

Rp 1.440

+5 (+0,35%)

JAKARTA. PT Kalbe Farma Tbk (KLBF), an issuer operating in the pharmaceutical sector, has inaugurated the construction of a radioisotope factory, which produces Fludeoxyglucose (FGD) for early detection of cancer.

Maria Teresa Fabiola, Corporate Secretary of KLBF, said that the factory is under the company's subsidiary, namely PT Global Onkolab Farma (GOF). The existence of this factory, said Maria, is expected to support the Positron Emission Tomography and Computed Tomography Scanning (PET/CT-Scan) examination services in hospitals.

"This is expected to strengthen the company's position, especially in the prescription drug segment," said Maria, in her official statement.

According to idnfinancials.com data, KLBF has cash and cash equivalents of IDR 3.85 trillion as of June 2024. The company's total assets are recorded at IDR 28.57 trillion and its total equity is IDR 23.54 trillion. (KR/LM)